Novartis hopes to kick-start its European launch of the RNAi-based PCSK-9 inhibitor Leqvio thanks to an innovative, access collaboration with NHS England which is designed to ensure 300,000 patients are proactively treated with the therapy over the next three years.
A prior Physician Views poll we ran in November last year suggests Leqvio is a clinically compelling addition to the treatment toolbox for adults with primary hypercholesterolaemia or mixed dyslipidaemia and our latest poll seeks to ascertain if and how this view has evolved and whether physicians welcome access deals like that agreed between Novartis and the NHS.
With US approval of Leqvio now expected in early 2022, this latest poll is fielding the following questions to cardiologists based in France, Germany, Italy, Spain and the UK…
Results and analysis will be published later this week for FirstWord Pharma PLUS subscribers and can be purchased by non-FirstWord Pharma PLUS subscribers. To be notified when they become available, click here
To read more Physician Views articles, click here.